These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20176894)

  • 1. Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
    Puyang X; Poulin DL; Mathy JE; Anderson LJ; Ma S; Fang Z; Zhu S; Lin K; Fujimoto R; Compton T; Wiedmann B
    Antimicrob Agents Chemother; 2010 May; 54(5):1981-7. PubMed ID: 20176894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A.
    Fernandes F; Ansari IU; Striker R
    PLoS One; 2010 Mar; 5(3):e9815. PubMed ID: 20352119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to cyclosporin A derives from mutations in hepatitis C virus nonstructural proteins.
    Arai M; Tsukiyama-Kohara K; Takagi A; Tobita Y; Inoue K; Kohara M
    Biochem Biophys Res Commun; 2014 May; 448(1):56-62. PubMed ID: 24751518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor.
    Goto K; Watashi K; Inoue D; Hijikata M; Shimotohno K
    Cancer Sci; 2009 Oct; 100(10):1943-50. PubMed ID: 19659609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance.
    Mathy JE; Ma S; Compton T; Lin K
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3267-75. PubMed ID: 18591281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro.
    Robida JM; Nelson HB; Liu Z; Tang H
    J Virol; 2007 Jun; 81(11):5829-40. PubMed ID: 17376913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.
    Madan V; Paul D; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 May; 146(5):1361-72.e1-9. PubMed ID: 24486951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B.
    Fernandes F; Poole DS; Hoover S; Middleton R; Andrei AC; Gerstner J; Striker R
    Hepatology; 2007 Oct; 46(4):1026-33. PubMed ID: 17600342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors.
    Chatterji U; Lim P; Bobardt MD; Wieland S; Cordek DG; Vuagniaux G; Chisari F; Cameron CE; Targett-Adams P; Parkinson T; Gallay PA
    J Hepatol; 2010 Jul; 53(1):50-6. PubMed ID: 20451281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
    Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach.
    Yang F; Robotham JM; Grise H; Frausto S; Madan V; Zayas M; Bartenschlager R; Robinson M; Greenstein AE; Nag A; Logan TM; Bienkiewicz E; Tang H
    PLoS Pathog; 2010 Sep; 6(9):e1001118. PubMed ID: 20886100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.
    Coelmont L; Hanoulle X; Chatterji U; Berger C; Snoeck J; Bobardt M; Lim P; Vliegen I; Paeshuyse J; Vuagniaux G; Vandamme AM; Bartenschlager R; Gallay P; Lippens G; Neyts J
    PLoS One; 2010 Oct; 5(10):e13687. PubMed ID: 21060866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity.
    Nevers Q; Ruiz I; Ahnou N; Donati F; Brillet R; Softic L; Chazal M; Jouvenet N; Fourati S; Baudesson C; Bruscella P; Gelin M; Guichou JF; Pawlotsky JM; Ahmed-Belkacem A
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.
    Hopkins S; Bobardt M; Chatterji U; Garcia-Rivera JA; Lim P; Gallay PA
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3888-97. PubMed ID: 22585215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A.
    Ciesek S; Steinmann E; Wedemeyer H; Manns MP; Neyts J; Tautz N; Madan V; Bartenschlager R; von Hahn T; Pietschmann T
    Hepatology; 2009 Nov; 50(5):1638-45. PubMed ID: 19821520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
    Coelmont L; Kaptein S; Paeshuyse J; Vliegen I; Dumont JM; Vuagniaux G; Neyts J
    Antimicrob Agents Chemother; 2009 Mar; 53(3):967-76. PubMed ID: 19104013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon.
    Ma S; Boerner JE; TiongYip C; Weidmann B; Ryder NS; Cooreman MP; Lin K
    Antimicrob Agents Chemother; 2006 Sep; 50(9):2976-82. PubMed ID: 16940091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.
    Garcia-Rivera JA; Bobardt M; Chatterji U; Hopkins S; Gregory MA; Wilkinson B; Lin K; Gallay PA
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5113-21. PubMed ID: 22802259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro.
    Yang F; Robotham JM; Nelson HB; Irsigler A; Kenworthy R; Tang H
    J Virol; 2008 Jun; 82(11):5269-78. PubMed ID: 18385230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophilin inhibitors for the treatment of HCV infection.
    Fischer G; Gallay P; Hopkins S
    Curr Opin Investig Drugs; 2010 Aug; 11(8):911-8. PubMed ID: 20721833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.